SELLAS Life Sciences 2025 net loss narrows, cash position strengthens

Sellas Life Sciences

19/03/2026 20:16

Overview

US biopharma firm's 2025 net loss narrowed from prior year

Company advanced pivotal Phase 3 REGAL trial and expanded SLS009 into earlier-line AML

Year-end cash position strengthened with $42.6 mln in Q1 2026 warrant proceeds

Outlook

SELLAS expects final analysis of Phase 3 REGAL trial after reaching 80 events

Company anticipates European enrollment for SLS009 clinical study in Q2 2026

SELLAS sees 2026 as a catalyst-rich year with continued clinical execution

Result Drivers

LOWER R&D SPENDING - Co said research and development expenses fell due to lower clinical trial and consulting costs after REGAL study enrollment completed

PIPELINE ADVANCEMENT - Co advanced pivotal Phase 3 REGAL trial and expanded SLS009 into earlier-line AML treatment

Company press release: ID:nGNX17w9L9

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-$26.86 mln
FY Basic EPS
-$0.25
FY Operating Expenses
$28.27 mln
FY Operating Income
-$28.27 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Sellas Life Sciences Group Inc is $7.50, about 51.5% above its March 18 closing price of $4.95

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)